Abstract
Metastatic colorectal carcinoma is among the most common tumour diseases and is a major contributor to the overall death rate from tumour diseases. The introduction of anti-VEGF and anti-EGFR monoclonal antibodies in 2004 was a milestone in treating metastatic colorectal carcinoma that has led to a significantly improved prognosis in metastatic disease.
The discovery of novel predictive markers has resulted in better selection of patients who can benefit from this treatment, and thus in a broader fulfilment of the purpose of targeted and tailored therapy. The present article deals with a brief history of development of anti-EGFR therapy in colorectal carcinoma.